Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00342771 · ClinicalTrials.gov registry record
An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 2,033
- Enrollment target
NCT00342771: Completed study, sponsored by National Cancer Institute (NCI).
NCT00342771 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,033 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00342771 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 2,033 participants
- Enrollment target
Study Summary
This study will examine the association of genetic variants and gene expression patterns with the risk of prostate cancer. There will be (It will include?) genotype analysis of blood DNA from 600 patients with the disease and from 600 healthy people, and there will be a gene expression analysis of prostate tumors. Prostate cancer is a leading cause of death among men in Western countries. It is estimated that 220,000 or more new cases of the disease will occur in the United States during 2004. The disease incidence is rising. About 25% to 30% of the cancers become aggressive. The nonhereditary disease rarely occurs in men who are younger than age 40. There are large differences in incidence by geography and race. The highest rates are seen among African-American men in the United States. Also, although Caucasians have a lower rate of disease incidence and mortality in the United States, the rates among them are high compared with rates in some European countries. The reasons for such differences are not well understood, but both environmental and genetic risk factors are thought to be involved. Patients ages 40 to 80 years who have had prostate cancer confirmed within the past 6 months, who reside in Baltimore City or adjacent metropolitan counties, and who were born in the United States may be eligible for this study. They will be recruited in collaboration with the Departments of Pathology and Urology at the University of Maryland and the Baltimore Veterans Affairs Medical Center. Those men serving as controls in this study will be identified through the Department of Motor Vehicles database and will be matched by age and race with the patients who have cancer. The study will include 600 participants with prostate cancer and 600 participants in the control group. Trained interviewers will administer two questionnaires. The primary questionnaire will be used to assess information such as medical and cancer history, tobacco use, current medications, occupational h
Primary Outcome
association of tobacco use, obesity, inflammation and anti- inflammatory drugs, sexual activity and sexually transmitted diseases, and ancestral markers with prostate cancer and lethal disease
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,033 participants |
| Start Date | 2004-11-08 |
| Est. Completion | 2020-08-06 |
What the finished NCT00342771 record still lists
NCT00342771 is an observational study that tracks outcomes without assigning an intervention. Its 2,033 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00342771 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00342771 about?
NCT00342771 is a clinical study titled "An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males". This study will examine the association of genetic variants and gene expression patterns with the risk of prostate cancer. There will be (It will include?) genotype analysis of blood DNA from 600 patients with the disease and from 600 healthy people, and there will be a gene expression analysis of p...
What is the current status of trial NCT00342771?
This trial is currently completed. The enrollment target is 2,033 participants. The study started on 2004-11-08. Estimated completion is 2020-08-06.
Who is sponsoring clinical trial NCT00342771?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05625659 · 2,032 participants · NA
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- NCT04216732 · 2,030 participants
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
- NCT06825897 · 2,039 participants · NA
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
- NCT05138718 · 2,041 participants
FDG an Myocardial Infarction: The PIAF Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI